SARS-CoV-2 Laboratory-Developed Tests

This Viewpoint reviews the regulatory oversight of laboratory-developed tests, discusses its recent policy permutations, and explores potential future considera

Related Keywords

New Jersey ,United States ,North Carolina ,Washington ,Kentucky ,Colorado ,California ,Indiana ,American ,Anna Eshoo ,Larry Bucshon ,Scott Gottlieb ,Diana Degette ,Frank Pallone ,Michael Bennet ,Xavier Becerra ,Eliy Adashi ,Patty Murray ,Alexm Azar ,Richard Burr ,Department Of Medical Science ,Pew Charitable ,Lepu Medical Technology ,House Committee On Energy ,Us Department Of Health ,Us Congress ,Brown University ,American Clinical Laboratory Association ,Centers For Medicare Medicaid Services ,Human Services ,Drug Administration ,Commerce Committee ,Abbott Molecular Inc ,Pensions Committee ,Innova Medical Group ,Clinical Laboratory Improvement Amendments ,Association Of Molecular Pathology ,Senate Health ,Medicaid Services ,Federal Food ,Cosmetic Act ,Emergency Use Authorization ,Oversight Subcommittee ,Consumer Policy ,Molecular Pathology ,Representative Frank Pallone ,House Committee ,Senator Patty Murray ,Secretary Becerra ,Representatives Pallone ,Empowered Diagnostics ,Acon Laboratories ,Verifying Accurate Leading Edge ,Representatives Degette ,Senators Michael Bennet ,Verified Innovative Testing ,American Laboratories Act ,Senator Rand Paul ,Medical Science ,Interest Disclosures ,Illumina Serves ,